GLP-1
Glucagon-Like Peptide-1
A receptor involved in incretin signaling and glucose-dependent metabolic regulation. Scientific literature continues to examine the role of GLP-1 receptor pathways in metabolic physiology.
PubMed Literature
INVESTIGATIONAL COMPOUND · NOT FDA APPROVED
HTL‑RTT
Retatrutide Research & Pen Technology
An overview of investigational triple-receptor science and the HTL-RTT pen-format product design.
Research Format Product
Regulatory Notice: Retatrutide is investigational and is not FDA approved.
This page is provided for scientific information only and does not facilitate the purchase,
administration, or medical use of any substance.
3
Receptor Targets
GLP-1 · GIP · GCG
Receptor Pathway Targets
IND
Investigational Status
HTL
Health Therapies Lifestyle
PRODUCT DESIGN
Designed with Simplicity in Mind
HTL-RTT Pen Design
Rotating Selector
A compact dial-style mechanism.
Click Feedback
Tactile feedback from the selector mechanism.
Compact Design
A streamlined, portable pen-style housing.
Physical design description only. Not cleared for human or veterinary administration.
PHARMACOLOGY
Understanding the Science Behind RTT
Retatrutide is a synthetic investigational peptide studied for its activity at three distinct hormone receptor pathways. Its receptor pharmacology is the subject of ongoing preclinical and clinical research. These are findings from investigational studies — not claims about the HTL-RTT product.
GIP
Glucose-Dependent Insulinotropic Polypeptide
A receptor associated with incretin signaling and metabolic regulation. Ongoing research investigates the pharmacological role of GIP receptor modulation within multi-receptor agonist frameworks.
PubMed LiteratureGCG
Glucagon Receptor
A receptor involved in glucose homeostasis and energy metabolism. Glucagon receptor biology is an area of active scientific inquiry within metabolic research.
PubMed Literature
PRODUCT SPECIFICATIONS
Product Overview
The following specifications reflect verified physical and compound information only. No purity percentages, sterility certifications, or analytical data are presented without independent verification.
| Specification | Detail | Notes |
|---|---|---|
| Product Designation | HTL-RTT | Health Therapies Lifestyle |
| Active Compound Identity | Retatrutide (investigational) | Synthetic peptide; not FDA approved |
| Receptor Targets | GLP-1 / GIP / Glucagon | Triple-receptor agonist pharmacology |
| Physical Format | Pen-style cylindrical housing | Navy-blue branded exterior |
| Packaging Configuration | Presentation case with interior insert | Pen housing + removable components |
| Selector Mechanism | Rotating dial with indexed positions | Tactile feedback design |
| Protective Cap | Friction-fit removable cap included | Matching housing finish |
| Lot Identification | Applied per batch | Batch records available where verified |
| Analytical Documentation | Pending independent verification | Will be posted when verified |
| Storage Information | Per applicable research protocols | Verified storage info provided with documentation |
| Intended Use | Research information & product-design showcase | Not for human or veterinary administration |
| Regulatory Status | Investigational — not FDA approved | No safety or efficacy claims made |
Analytical test results, purity values, sterility certifications, and Certificates of Analysis are not displayed on this page. Such records will be posted only when independently verified and applicable to a specific batch.
TRANSPARENCY
Research Documentation
Verified documentation, batch records, and analytical results will appear below when available and independently confirmed. Scientific literature references are provided where publicly accessible.
Available References
Awaiting Verification
Analytical Testing Records
Batch-specific analytical documentation — posted only when independently verified.
Lot Traceability Records
Lot-specific identification and chain-of-custody records — posted when available.
Compound Identity Documentation
Molecular identity records for specific batches — posted upon verification.
INFORMATION
Frequently Asked Questions
Scientific, design, and regulatory clarity about HTL-RTT.
Product Identity
HTL-RTT is the Health Therapies Lifestyle designation for a proposed investigational retatrutide research product concept, presented in a pen-format housing. This website is a scientific information and product-design informational resource only.
Retatrutide (also known by the research designation LY3437943) is an investigational synthetic peptide studied for its activity at GLP-1, GIP, and glucagon receptors. It is the subject of registered clinical trials and published peer-reviewed scientific literature.
No. Retatrutide is investigational and has not received FDA approval. It remains under active clinical investigation. No claims of regulatory approval, safety certification, or clinical efficacy are made on this website.
Pen Design
The HTL-RTT pen features a navy-blue cylindrical housing with HTL-RTT branding applied directly to the barrel. It includes a rotating selector mechanism, a removable protective cap, and is supplied in a branded presentation case with organized interior compartments.
The presentation set includes the branded pen housing, a removable protective cap, multiple removable components stored in dedicated compartments, and the branded presentation case with molded interior insert. Component descriptions are provided for identification purposes only.
No. This website does not represent HTL-RTT as an approved, sterile, or injection-ready product. No claims of sterility, pharmaceutical-grade manufacture, clearance for human use, or suitability for administration of any kind are made. This information is for research product design and scientific informational purposes only.
Science & Documentation
Triple-receptor agonism refers to a molecule capable of activating three different receptor types simultaneously. In retatrutide's case, this refers to the GLP-1, GIP, and glucagon receptors. The scientific significance of this multi-receptor activity is the subject of ongoing peer-reviewed research and registered clinical trials.
Links to publicly available peer-reviewed retatrutide research are provided in the Research Documentation section above, including direct links to PubMed and ClinicalTrials.gov. Batch-specific analytical records and compound identity documentation will be displayed only when independently verified.
This informational website does not represent HTL-RTT as an approved or suitable product for human or veterinary use. No dosing, injection, assembly, or administration instructions are provided anywhere on this website. The page is a scientific information and product-design showcase only.